The latest pharmaceutical sales and marketing news
C4X Discovery Holdings has announced that it has received a milestone payment of $11m from AstraZeneca, which was triggered by the preclinical progress of C4XD’s NRF2 activator programme.
GSK and Aiolos Bio have announced that they have entered into an agreement for GSK to acquire Aiolos for an initial $1bn upfront payment along with up to $400m in success-based regulatory milestone payments.
Sanofi and Inhibrx, Inc have announced that they have entered into a definitive agreement for Sanofi to acquire Inhibrx following the spin-off of non-inbrx-101 assets into New Inhibrx.
Merck (known as MSD outside of the US and Canada) and Harpoon Therapeutics have announced that they have entered a definitive agreement for Merck, through a subsidiary, to acquire Harpoon for an approximate total equity value of $680m or $23 per share.
Autifony Therapeutics has announced that it has entered an exclusive global licensing agreement with Jazz Pharmaceuticals for up to $770.5m, with the intention of discovering and developing drug candidates to target two different ion channel targets associated with neurological disorders.
Astellas Pharma and Propella Therapeutics have announced that they have entered a merger agreement in which Astellas will acquire Propella for approximately $175m.
Roche has announced that it has entered into a definitive agreement to acquire Telavant Holdings, a Roivant company, owned by Roivant sciences and Pfizer.
US-based clinical stage biopharmaceutical company Avalyn Pharma has announced that it has raised $175m in series c financing to continue its portfolio of inhalation therapies.
Acesion Pharma has announced that it has closed an oversubscribed €45m series b financing round.
Bristol Myers Squibb (BMS) and Mirati Therapeutics have announced that they have entered into a definitive agreement under which BMS will acquire Mirati for $58 per share, or a total value of $4.8bn.
Eli Lilly and POINT Biopharma have announced a definitive agreement for Lilly to acquire POINT to expand its pipeline of clinical and preclinical-stage radioligand therapies for the treatment of cancer.
Alfasigma and Intercept Pharmaceuticals have announced that they have entered into a definitive merger agreement, meaning Alfasigma will acquire Intercept for $19 per share.